Published mark
Tarsus Pharmaceuticals, Inc.
NASDAQ: TARS. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:695ba9c5-e4b2-488d-a358-29f2957449d4
- SEC CIK
- 0001819790
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 21, 2026
- Newest evidence
- Apr 28, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Bobak AzamianSince Apr 28, 2026
- Chair
- Bobak Azamian, M.D., Ph.D.Lead independent: Wendy Yarno, MBA
- Independent
- Not published7 directors published
- Published claims
- 452 distinct sources
- Evidence records
- 60 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 6 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Bobak Azamian executive of Tarsus Pharmaceuticals, Inc., effective 2026-04-28.
EffectiveEffective Apr 28, 2026E4
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| President, Chief Executive Officer, and Board Chairman | Bobak Azamian | Apr 2026 | current | Source reportedE4 |
| General Counsel and Secretary | Bryan Wahl | Apr 2026 | current | Source reportedE5 |
| Chief Commercial Officer | Aziz Mottiwala, MBA | Not captured | unknown | Source reportedE2 |
| President and Chief Executive Officer | Bobak Azamian, M.D., Ph.D. | Not captured | unknown | Source reportedE2 |
| General Counsel and Secretary | Bryan Wahl, M.D., J.D. | Not captured | unknown | Source reportedE2 |
| Chief Human Resources Officer | Dianne Whitfield, MSW | Not captured | unknown | Source reportedE2 |
| Chief Medical Officer | Elizabeth Yeu-Lin, M.D. | Not captured | unknown | Source reportedE2 |
| Chief Financial Officer and Chief Strategy Officer | Jeffrey Farrow | Not captured | unknown | Source reportedE2 |
| Chief Operating Officer | Seshadri Neervannan, Ph.D. | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence7 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Andrew Goldberg | Independence not published | 2020 | AUDIT COMMITTEEnominating and corporate governance Committeescience and technology committee | Source reportedE3 |
| Bhaskar Chaudhuri | Independence not published | 2019 | compensation committeenominating and corporate governance Committeescience and technology committee | Source reportedE3 |
| David E.I. Pyott | Independence not published | 2015 | compensation committeenominating and corporate governance Committee | Source reportedE3 |
| Katherine Goodrich | Independence not published | 2024 | AUDIT COMMITTEE | Source reportedE3 |
| Scott Morrison | Independence not published | 2022 | AUDIT COMMITTEE | Source reportedE3 |
| Wendy Yarno | Independence not published | 2022 | compensation committee | Source reportedE3 |
| William J. Link | Independence not published | 2017 | compensation committeenominating and corporate governance Committeescience and technology committee | Source reportedE3 |
| Andrew Goldberg, M.D. | Independent | Not published | None published | Source reportedE2 |
| Bhaskar Chaudhuri, Ph.D. | Independent | Not published | None published | Source reportedE2 |
| Bobak Azamian, M.D., Ph.D. | Not independentChair | Not published | Chief Executive Officer and Chairman | Source reportedE2 |
| David E.I. Pyott, MBA | Independent | Not published | None published | Source reportedE2 |
| Katherine Goodrich, M.D. | Independent | Not published | None published | Source reportedE2 |
| Wendy Yarno, MBA | IndependentLead Independent | Not published | None published | Source reportedE2 |
| William J. Link, Ph.D. | Independent | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| AUDIT COMMITTEE | Not published | Andrew Goldberg, Katherine Goodrich, Scott Morrison | Not described in the published record |
| Chief Executive Officer and Chairman | Not published | Bobak Azamian, M.D., Ph.D. | Not described in the published record |
| compensation committee | Not published | Bhaskar Chaudhuri, David E.I. Pyott, Wendy Yarno, William J. Link | Not described in the published record |
| nominating and corporate governance Committee | Not published | Andrew Goldberg, Bhaskar Chaudhuri, David E.I. Pyott, William J. Link | Not described in the published record |
| science and technology committee | Not published | Andrew Goldberg, Bhaskar Chaudhuri, William J. Link | Not described in the published record |
Committee RecordAUDIT COMMITTEE: Chair not stated; Members Andrew Goldberg; Katherine Goodrich; Scott Morrison
Committee AppointmentAndrew Goldberg: member, AUDIT COMMITTEE
Committee AppointmentKatherine Goodrich: member, AUDIT COMMITTEE
Committee AppointmentScott Morrison: member, AUDIT COMMITTEE
Committee Recordcompensation committee: Chair not stated; Members Bhaskar Chaudhuri; David E.I. Pyott; Wendy Yarno; William J. Link
Committee AppointmentBhaskar Chaudhuri: member, compensation committee
Committee AppointmentDavid E.I. Pyott: member, compensation committee
Committee AppointmentWendy Yarno: member, compensation committee
Committee AppointmentWilliam J. Link: member, compensation committee
Committee Recordnominating and corporate governance Committee: Chair not stated; Members Andrew Goldberg; Bhaskar Chaudhuri; David E.I. Pyott; William J. Link
Committee AppointmentAndrew Goldberg: member, nominating and corporate governance Committee
Committee AppointmentBhaskar Chaudhuri: member, nominating and corporate governance Committee
Committee AppointmentDavid E.I. Pyott: member, nominating and corporate governance Committee
Committee AppointmentWilliam J. Link: member, nominating and corporate governance Committee
Committee Recordscience and technology committee: Chair not stated; Members Andrew Goldberg; Bhaskar Chaudhuri; William J. Link
Committee AppointmentAndrew Goldberg: member, science and technology committee
Committee AppointmentBhaskar Chaudhuri: member, science and technology committee
Committee AppointmentWilliam J. Link: member, science and technology committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerBobak Azamian, President, Chief Executive Officer, and Board Chairman, from Apr 28, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingTARS (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 21, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameTarsus Pharmaceuticals, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Bobak AzamianPresident, Chief Executive Officer, and Board Chairmancompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:20
- Bryan WahlGeneral Counsel and Secretarycompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:22
- Aziz Mottiwala, MBAChief Commercial Officercompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:19
- Bobak Azamian, M.D., Ph.D.President and Chief Executive Officer; President, Chief Executive Officer and Chairmancompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:21, company:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:5
- Bryan Wahl, M.D., J.D.General Counsel and Secretarycompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:23
- Dianne Whitfield, MSWChief Human Resources Officercompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:24
- Elizabeth Yeu-Lin, M.D.Chief Medical Officercompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:25
- Jeffrey FarrowChief Financial Officer and Chief Strategy Officercompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:26
- Seshadri Neervannan, Ph.D.Chief Operating Officercompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:27
- Andrew GoldbergDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:6
- Bhaskar ChaudhuriDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:8
- David E.I. PyottDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:10
- Katherine GoodrichDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:12
- Scott MorrisonDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:14
- Wendy YarnoDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:15
- William J. LinkDirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:17
- Andrew Goldberg, M.D.Directorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:7
- Bhaskar Chaudhuri, Ph.D.Directorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:9
- David E.I. Pyott, MBADirectorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:11
- Katherine Goodrich, M.D.Directorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:13
- Wendy Yarno, MBALead Independent Directorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:16
- William J. Link, Ph.D.Directorcompany:695ba9c5-e4b2-488d-a358-29f2957449d4:leadership_role:18
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 6 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 21, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 28, 2026. Retrieved Sep 13, 2026. Cited by 14 Claims.
- E3sec proxy. Published Apr 28, 2026. Retrieved Sep 2, 2026. Cited by 7 Claims.
- E4sec filing. Published Apr 28, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 28, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E6governance_people_committees. sec proxy. Cited by 18 Claims.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 21, 2026- Bobak Azamian executive of Tarsus Pharmaceuticals, Inc., effective 2026-04-28.
- Bryan Wahl executive of Tarsus Pharmaceuticals, Inc., effective 2026-04-28.
- Katherine Goodrich seat on Tarsus Pharmaceuticals, Inc., effective 2024-01-01.
- Scott Morrison seat on Tarsus Pharmaceuticals, Inc., effective 2022-01-01.
- Wendy Yarno seat on Tarsus Pharmaceuticals, Inc., effective 2022-01-01.
- Andrew Goldberg seat on Tarsus Pharmaceuticals, Inc., effective 2020-01-01.
- Bhaskar Chaudhuri seat on Tarsus Pharmaceuticals, Inc., effective 2019-01-01.
- William J. Link seat on Tarsus Pharmaceuticals, Inc., effective 2017-01-01.
- David E.I. Pyott seat on Tarsus Pharmaceuticals, Inc., effective 2015-01-01.